Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of loureirin A to preparation of medicine for preventing or treating diabetic angiopathy

A technology of diabetic blood vessels and dragon blood, which is applied in cardiovascular system diseases, drug combinations, metabolic diseases, etc., can solve problems such as unreported effects, achieve the effects of inhibiting cell apoptosis, improving the decline of GSH activity, and reducing the content

Active Publication Date: 2020-02-07
JINAN UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of astragalus in the treatment of MGO-induced diabetic vasculopathy has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of loureirin A to preparation of medicine for preventing or treating diabetic angiopathy
  • Application of loureirin A to preparation of medicine for preventing or treating diabetic angiopathy
  • Application of loureirin A to preparation of medicine for preventing or treating diabetic angiopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] 1. Experimental materials Human umbilical vein endothelial cells (HUVEC) culture

[0038] 1.1 Culture conditions

[0039] Inoculate HUVEC (derived from ATCC) in DMEM medium containing 10% (v / v) fetal bovine serum, and place it at 37°C, 5% CO 2 In the incubator. The medium was changed every 2 days.

[0040] 1.2 Cell Passaging

[0041] Take a bottle of HUVEC and observe the cells under an inverted phase-contrast microscope. If they grow into a dense monolayer, pass them down. Gently shake the culture flask several times to suspend the debris floating on the surface of the cells, then pour out the culture solution together, and add 2 mL of phosphate buffer solution (PBS, 10mM, pH=7.4) into the culture flask, and shake it gently. Pour and repeat 2 times. Add 1 mL of trypsin solution containing 0.25% (w / v) EDTA to cover the bottom of the bottle, moisten the entire cell layer, and place it in an incubator at 37°C for 2 minutes until it is confirmed that the cells shrink and become...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of loureirin A to preparation of medicine for preventing or treating diabetic angiopathy. The application of the loureirin A to the preparation of the medicine forpreventing or treating the diabetic angiopathy is provided based on the fact that the inventor finds for the first time that the loureirin A has an obvious curative effect on the diabetic angiopathy caused by vascular endothelial injury caused by methylglyoxal. The methylglyoxal is a highly active glucose toxic metabolite, and is greatly increased in patients with diabetes, especially in patientswith complications of the diabetes. The curative effect of the loureirin A on the diabetic angiopathy caused by the vascular endothelial injury caused by the methylglyoxal is specifically reflected inimproving cell morphology, increasing the cell survival rate, reducing the apoptosis rate, alleviating cell oxidative stress injury, removing the methylglyoxal and reducing the content of advanced glycosylation end products and the like.

Description

Technical field [0001] The present invention relates to the application of Loureirin A, in particular to the application of Loureirin A in the preparation of drugs for preventing or treating diabetic vascular disease. Background technique [0002] According to authoritative statistics, as of 2017, the number of diabetic patients in my country has reached 114 million. Globally, according to the latest statistics of the International Diabetes Federation (IDF), it is about 425 million. The total number of patients is estimated to be 2040. Will rise to 700 million. According to Lancet's latest data, the number of adult diabetic patients worldwide has more than tripled in the 30 years from 1980 to 2014. Diabetes is a lifelong metabolic disease characterized by chronic hyperglycemia. Long-term high blood sugar in the patient's body can cause damage to multiple organs throughout the body. According to statistics, 1 person will die of diabetes complications every 6 seconds in the world....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/12A61P3/10A61P9/10A61P9/00
CPCA61K31/12A61P3/10A61P9/00A61P9/10
Inventor 聂红汤丹肖伟饶娇雨朱涛
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com